Champions Oncology (NASDAQ:CSBR) Stock Passes Below 200-Day Moving Average – Should You Sell?

Champions Oncology, Inc. (NASDAQ:CSBR)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.14 and traded as low as $5.26. Champions Oncology shares last traded at $5.76, with a volume of 2,934 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Champions Oncology presently has a consensus rating of “Sell”.

Champions Oncology Stock Down 2.8%

The firm has a 50 day simple moving average of $6.00 and a two-hundred day simple moving average of $6.12. The stock has a market capitalization of $73.62 million, a P/E ratio of -66.25 and a beta of 0.40.

Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings results on Monday, July 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.06. Champions Oncology had a negative return on equity of 27.48% and a negative net margin of 1.87%.The company had revenue of $13.84 million for the quarter, compared to analyst estimates of $12.89 million.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Champions Oncology by 1.9% in the third quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock worth $2,158,000 after acquiring an additional 6,229 shares during the last quarter. Mink Brook Asset Management LLC acquired a new position in Champions Oncology during the 4th quarter worth approximately $555,000. Acadian Asset Management LLC increased its position in Champions Oncology by 28.7% during the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 8,814 shares in the last quarter. Goldman Sachs Group Inc. bought a new position in Champions Oncology in the 1st quarter valued at approximately $201,000. Finally, Jane Street Group LLC bought a new position in Champions Oncology in the 1st quarter valued at approximately $200,000. Institutional investors and hedge funds own 41.30% of the company’s stock.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.